Cargando…
KRAS-mutant colon cancer cells respond to combined treatment of ABT263 and axitinib
Significant challenges to develop selective and effective pharmacological inhibitors for important oncoproteins like RAS continue impeding the success to treat cancers driven by such mutations. In the present study, the ABT263 and axitinib combination imposed synergistic effects on RAS-mutant colon...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Portland Press Ltd.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400663/ https://www.ncbi.nlm.nih.gov/pubmed/30674639 http://dx.doi.org/10.1042/BSR20181786 |